A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma
Author:
Malaina IkerORCID, Martínez LuisORCID, Montoya Juan Manuel, Alonso SantosORCID, Boyano María DoloresORCID, Asumendi AintzaneORCID, Izu Rosa, Sanchez-Diez Ana, Cancho-Galan Goikoane, M. de la Fuente IldefonsoORCID
Abstract
Background: The main purpose of this article is to introduce a universal mathematics-aided vaccine design method against malignant melanoma based on neoantigens. The universal method can be adapted to the mutanome of each patient so that a specific candidate vaccine can be tailored for the corresponding patient. Methods: We extracted the 1134 most frequent mutations in melanoma, and we associated each of them to a vector with 10 components estimated with different bioinformatics tools, for which we found an aggregated value according to a set of weights, and then we ordered them in decreasing order of the scores. Results: We prepared a universal table of the most frequent mutations in melanoma ordered in decreasing order of viability to be used as candidate vaccines, so that the selection of a set of appropriate peptides for each particular patient can be easily and quickly implemented according to their specific mutanome and transcription profile. Conclusions: We have shown that the techniques that are commonly used for the design of personalized anti-tumor vaccines against malignant melanoma can be adapted for the design of universal rankings of neoantigens that originate personalized vaccines when the mutanome and transcription profile of specific patients is considered, with the consequent savings in time and money, shortening the design and production time.
Funder
Basque Government UPV/EHU and BCAM
Subject
Paleontology,Space and Planetary Science,General Biochemistry, Genetics and Molecular Biology,Ecology, Evolution, Behavior and Systematics
Reference45 articles.
1. Peng, M., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., and Zeng, Z. (2019). Neoantigen vaccine: An emerging tumor immunotherapy. Molecular Cancer, 18. 2. Okada, M., Shimizu, K., and Fujii, S.I. (2022). Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy. Int. J. Mol. Sci., 23. 3. Improving cancer immunotherapies through empirical neoantigen selection;Nogueira;Trends Cancer,2018 4. Neoantigens in the immuno-oncology space;Arlen;Future Oncol.,2017 5. (2022, October 26). Clinical Trials, Available online: https://clinicaltrials.gov/ct2/show/NCT02950766.
|
|